Navigation Links
Lakewood-Amedex Announces Its Novel Bisphosphocin Class Of Antimicrobials Are Active Against NDM-1 Positive Bacterial Strains
Date:7/31/2013

SARASOTA, Fla., July 31, 2013 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that a recent series of in vitro studies conducted by ImQuest BioSciences of Fredrick, MD, have demonstrated that its novel class of antimicrobials, named bisphosphocins, have proven effective at killing bacterial strains carrying the NDM-1 plasmid.  These studies expand on previously published experiments demonstrating Nu-3 to be effective in killing multi-drug resistant bacteria and highlight the potential of this important new class of antimicrobials.  Specifically, the studies revealed that Nu-3 was rapidly bactericidal to NDM-1 positive Klebsiella pneumonia BAA2146 and Escherichia coli BAA2469, both of which are resistant to more than 5 classes of antibiotics, generating a greater than 5 log reduction in bacterial counts or 100% kill with a fifteen minute incubation at room temperature, which is less time than these bacteria take to replicate.This result is significant because the unique bisphosphocin mechanism of action eliminates many of the current problems in the treatment of bacterial or fungal diseases, namely the development of microbial resistance, and can eradicate slow growing or stationary bacteria and bacterial biofilms, constantly a major problem for the medical community.  Traditional antibiotics only inhibit bacterial growth, typically through a single target molecule, thus requiring a prolonged exposure and that provides an opportunity for the bacteria to mutate and become resistant or dormant to avoid the antibiotic affecting them.  In the case of bisphosphocins, the effect is directly bactericidal and does not depend on the bacteria being in a growth cycle, eliminating any opportunity for the development of resistance and increasing their potency when bacteria become dormant or form a biofilm. 

The Company is fast
'/>"/>

SOURCE Lakewood-Amedex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lakewood-Amedex Announces Results Demonstrating The More Rapid Direct Bactericidal Activity Of Novel Bisphosphocin Class Of Antimicrobials
2. Serina Therapeutics Announces Agreement with the Scripps Research Institute for Development of Polymer-Antibody Drug Conjugates
3. Trovagene, Inc. Announces Closing of $15 Million Registered Direct Offering of Common Stock
4. CryoLife Announces First European Implant Of HeRO Graft
5. North South Holdings Inc. Announces its First Settlement and License Agreement.
6. Naurex Announces Issuance Of New Patent For Novel Antidepressant GLYX-13
7. BioDrain Announces Medical Advisory Board Comprised of Top Doctors and Healthcare Executive
8. NeuroSigma Announces FDA Approval to Commence Phase III Trial
9. The Galien Foundation Announces 2013 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology"
10. IRIDEX Announces Second Quarter 2013 Conference Call and Release Date
11. Amgen Announces Webcast of 2013 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... SAN DIEGO , 29. ... Ltd. (nachstehend Daiichi Sankyo) (TSE: 4568) und ... gaben heute gemeinsam eine definitive Fusionsvereinbarung bekannt, ... von Ambit Biosciences für 15 US-Dollar je ... anschließenden Zusammenschluss mit einem Tochterunternehmen von Daiichi ...
(Date:9/29/2014)... IRVING, Texas , Sept. 29, 2014 /PRNewswire/ ... 340B Drug Pricing Program, has announced that it ... Services Administration (HRSA) to continue serving in its ... 2019. Apexus, which has held this position for ... with more than 25,000 safety-net provider locations, drug ...
(Date:9/29/2014)... SEATTLE , Sept. 29, 2014 ... leverages Next Generation Sequencing to profile the adaptive ... a Scientific Advisory Board to provide strategic and ... diagnostic suite of assays in the diagnosis and ... initial focus of the SAB will be to ...
Breaking Medicine Technology:Daiichi Sankyo wird Ambit Biosciences übernehmen 2Daiichi Sankyo wird Ambit Biosciences übernehmen 3Daiichi Sankyo wird Ambit Biosciences übernehmen 4Daiichi Sankyo wird Ambit Biosciences übernehmen 5Daiichi Sankyo wird Ambit Biosciences übernehmen 6Daiichi Sankyo wird Ambit Biosciences übernehmen 7Daiichi Sankyo wird Ambit Biosciences übernehmen 8Apexus Wins HRSA Contract to Remain Prime Vendor of 340B Program 2Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 2Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 3
... Medical Inc. (TMI),announced today that it has been ... commercialize in Europe the Antares(TM) Coronary,Stent System, a ... use,at or near coronary bifurcations., Representing the ... potential use in a quarter of the 2.2 ...
... Line Clinical Results Expected in November 2008, BOTHELL, ... ) announced today the completion of patient enrollment and ... evaluate the safety and,efficacy of its formulation of 12-hour ... expects to report top-line,results from this pivotal trial in ...
Cached Medicine Technology:TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3
(Date:9/30/2014)... KY (PRWEB) September 30, 2014 Up ... people in the United States alone have sleep apnea. ... and of those treated, many cannot tolerate their prescribed ... supplied through a nasal mask) – which supports the ... night’s sleep has become especially valuable, and increasingly difficult ...
(Date:9/30/2014)... compared with placebo did not reduce hospital length of ... mortality, or the risk of death at 6 months ... ill, according to a study published in JAMA ... coincide with its presentation at the European Society of ... prevalence of low vitamin D levels has been confirmed ...
(Date:9/30/2014)... Youth Town’s annual BBQ/Music Festival will take ... p.m. at the Youth Town campus (3641 Youth Town ... family-oriented festival, which will offer music, food and games. ... car show, arts and crafts fair, music, championship barbeque ... Lightning McQueen and Mater from the hit Disney movie ...
(Date:9/30/2014)... September 30, 2014 Top10inaction.com, one of ... on ranking and reviewing all essential categories in daily ... announced the best liquid foundation at http://top10inaction.com/liquid-foundations/ , ... is named as the best foundation of them all. ... well as high end brands, hence customers have more ...
(Date:9/30/2014)... September 30, 2014 3M has added four ... high bond tapes. 3M 5906 , 3M 5907 ... are conformable VHBs which help create the strongest bond possible ... are used for bonding to difficult surfaces such as paints, ... 5906, 5907, 5908, and 5905 are designed specifically for electronic ...
Breaking Medicine News(10 mins):Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 2Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 3Health News:High-dose vitamin D for ICU patients who are vitamin D deficient does not improve outcomes 2Health News:Yves Saint Laurent is Named As Best Liquid Foundation 2014 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 3
... The University of Pittsburgh Cancer Institute (UPCI) today ... F. Shapira BRCA Cancer Research Program. BRCA 1 and ... the risk of breast, prostate, ovarian and pancreatic cancers. ... this research program to UPCI, said Ronald Herberman, M.D., ...
... people on trial were granted the right to an interpreter ... by UCL (University College London) scientists. The use of family ... teachers and eventually written testimony, which may have disadvantaged the ... British Sign Language was emerging. , The study, ...
... debt and expands available credit facility, HATBORO, ... leading technology provider of enterprise mobility solutions for,the ... has,completed a senior debt financing of up to ... HTGC )., (Logo: http://www.newscom.com/cgi-bin/prnh/20071101/NETH165LOGO ...
... country and online offer opportunity to save a life, ... of adding,46,000 new members to the marrow Registry during ... Marrow Donor Program,s largest,annual awareness campaign, kicks off today., ... other,life-threatening diseases, a marrow transplant offers a second chance ...
... and atypical cells also indicate high risk of second cancer, study ... have been diagnosed with breast cancer, having a known mutation in ... second cancer, and many of these women choose to have their ... However, new research suggests that women who don,t have ...
... May 5 Facet Solutions, Inc., a privately,held ... announced the successful completion of a scientific,evaluation for ... The study,evaluated the combination of Facet Solutions, Anatomic ... device in a,finite element model. The details of ...
Cached Medicine News:Health News:Research program focuses on genetic mutations and cancer risk 2Health News:'Deaf by God' tried in Old Bailey records 2Health News:'Deaf by God' tried in Old Bailey records 3Health News:InfoLogix Completes $25 Million Senior Debt Financing 2Health News:InfoLogix Completes $25 Million Senior Debt Financing 3Health News:National Marrow Donor Program(R) Kicks off National Awareness Campaign 2Health News:National Marrow Donor Program(R) Kicks off National Awareness Campaign 3Health News:BRCA Mutations Don't Spot All High-Risk Women 2Health News:BRCA Mutations Don't Spot All High-Risk Women 3Health News:Facet Solutions, Inc. Completes Combination Facet Joint and Disc Replacement Study 2
... The PRO6000 power supply ... Thermo's power supply product offering. ... proteomic and genomic electrophoresis. This ... to proteomic applications such as ...
... voltage power supply, the 105 is very simple ... switch control the output, which is variable in ... two-position switch toggles the bright LED display from ... is equipped with an over current detector for ...
... supply is capable of producing up to 250 ... operates in constant voltage or constant current with ... over from one mode of operation to the ... A dual function, auto ranging 24-hour up/down ...
... is designed for horizontal and vertical gel ... be accomplished. In this power supply model, ... current or constant voltage. Four sets of ... connected simultaneously. This power supply's light, compact ...
Medicine Products: